Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Mary Jane Masson Hinrichs"'
Autor:
Patrick H. van Berkel, Ronald Herbst, David A. Tice, Steve Coats, John A. Hartley, Philip W. Howard, Neil H. Bander, Sae Kim, He Liu, Eva Corey, Simon Chivers, Mary Jane Masson Hinrichs, Martin Korade, Patrick Strout, Kevin Schifferli, Ravinder Tammali, Karma Dacosta, Wanda King, Charles E. Britten, Sandamali Dissanayake, Halla W. Reinert, Lauren Adams, Simon Corbett, Francois Bertelli, Nazzareno Dimasi, Kapil Vashisht, Ryan Fleming, Francois D'Hooge, Peter Tyrer, Noel R. Monks, Carin E.G. Havenith, David G. Williams, Francesca Zammarchi, Song Cho
Supplementary Figure S1. Retention of MEDI3726 activity in human, cynomolgus monkey plasma or PBS for up to 7 days. Supplementary Figure S2. Kaplan-Meier analysis of the Time-to-Endpoint Survival in the (A) LNCaP, (B) CWR22Rv1, and (C) PC-3 Xenograft
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0fba3333e7f01b57533060b9dc76a71f
https://doi.org/10.1158/1535-7163.22505436.v1
https://doi.org/10.1158/1535-7163.22505436.v1
Autor:
Patrick H. van Berkel, Ronald Herbst, David A. Tice, Steve Coats, John A. Hartley, Philip W. Howard, Neil H. Bander, Sae Kim, He Liu, Eva Corey, Simon Chivers, Mary Jane Masson Hinrichs, Martin Korade, Patrick Strout, Kevin Schifferli, Ravinder Tammali, Karma Dacosta, Wanda King, Charles E. Britten, Sandamali Dissanayake, Halla W. Reinert, Lauren Adams, Simon Corbett, Francois Bertelli, Nazzareno Dimasi, Kapil Vashisht, Ryan Fleming, Francois D'Hooge, Peter Tyrer, Noel R. Monks, Carin E.G. Havenith, David G. Williams, Francesca Zammarchi, Song Cho
Table S1. P values of comparing time to endpoint survival among all treatment groups in the LNCaP xenograft study Table S2. Summary of PSMA IHC in xenograft tumors Table S3. P values of comparing time to endpoint survival among all treatment groups i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::231399c1a6b9388e7ff58e433d77c143
https://doi.org/10.1158/1535-7163.22505430
https://doi.org/10.1158/1535-7163.22505430
Autor:
Patrick H. van Berkel, Ronald Herbst, David A. Tice, Steve Coats, John A. Hartley, Philip W. Howard, Neil H. Bander, Sae Kim, He Liu, Eva Corey, Simon Chivers, Mary Jane Masson Hinrichs, Martin Korade, Patrick Strout, Kevin Schifferli, Ravinder Tammali, Karma Dacosta, Wanda King, Charles E. Britten, Sandamali Dissanayake, Halla W. Reinert, Lauren Adams, Simon Corbett, Francois Bertelli, Nazzareno Dimasi, Kapil Vashisht, Ryan Fleming, Francois D'Hooge, Peter Tyrer, Noel R. Monks, Carin E.G. Havenith, David G. Williams, Francesca Zammarchi, Song Cho
Supplementary Methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c4924695dc910a4941d12258d7652e0
https://doi.org/10.1158/1535-7163.22505433.v1
https://doi.org/10.1158/1535-7163.22505433.v1
Autor:
Patrick H. van Berkel, Ronald Herbst, David A. Tice, Steve Coats, John A. Hartley, Philip W. Howard, Neil H. Bander, Sae Kim, He Liu, Eva Corey, Simon Chivers, Mary Jane Masson Hinrichs, Martin Korade, Patrick Strout, Kevin Schifferli, Ravinder Tammali, Karma Dacosta, Wanda King, Charles E. Britten, Sandamali Dissanayake, Halla W. Reinert, Lauren Adams, Simon Corbett, Francois Bertelli, Nazzareno Dimasi, Kapil Vashisht, Ryan Fleming, Francois D'Hooge, Peter Tyrer, Noel R. Monks, Carin E.G. Havenith, David G. Williams, Francesca Zammarchi, Song Cho
Prostate-specific membrane antigen (PSMA) is a membrane-bound glutamate carboxypeptidase that is highly expressed in nearly all prostate cancers with the highest expression in metastatic castration-resistant prostate cancer (mCRPC). The prevalence of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::321b0f7676a6116fbc4184f047275750
https://doi.org/10.1158/1535-7163.c.6538059.v1
https://doi.org/10.1158/1535-7163.c.6538059.v1
Autor:
Rakesh Dixit, Nazzareno Dimasi, Phillip W. Howard, Arnaud Tiberghien, Luke Masterson, Cui Chen, Neki Patel, Shannon Breen, Patricia C. Ryan, Molly Reed, Marlon Rebelatto, Kapil Vashisht, Binyam Bezabeh, Jay Harper, Haihong Zhong, Michele Gunsior, Xiang Qing Yu, Shameen Afif-Rider, Bo Zheng, Pauline M. Ryan, Mary Jane Masson Hinrichs
Purpose: To use preclinical models to identify a dosing schedule that improves tolerability of highly potent pyrrolobenzodiazepine dimers (PBDs) antibody drug conjugates (ADCs) without compromising antitumor activity.Experimental Design: A series of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09bff01a2c0da935c0ea2819fe0a9ef9
https://doi.org/10.1158/1078-0432.c.6526344
https://doi.org/10.1158/1078-0432.c.6526344
Autor:
Rakesh Dixit, Nazzareno Dimasi, Phillip W. Howard, Arnaud Tiberghien, Luke Masterson, Cui Chen, Neki Patel, Shannon Breen, Patricia C. Ryan, Molly Reed, Marlon Rebelatto, Kapil Vashisht, Binyam Bezabeh, Jay Harper, Haihong Zhong, Michele Gunsior, Xiang Qing Yu, Shameen Afif-Rider, Bo Zheng, Pauline M. Ryan, Mary Jane Masson Hinrichs
Supplementary Figure 1. (a,b) Structure of the payloads SG3249 and SG3400; Supplementary Figure 2. PK concentration vs. time profile of R347-SG3400 in monkeys after either a single IV injection of 4.5mg/kg or 3 weekly IV injections of 1.5mg/kg; Suppl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18262bd2056388988e5e07e301278edb
https://doi.org/10.1158/1078-0432.22466538
https://doi.org/10.1158/1078-0432.22466538